Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: Masking of HPV52 by HPV16 in anogenital specimens

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 1, 2015, Pages 286-290

  Tota, Joseph E ^a   Ramanakumar, Agnihotram V ^a   Villa, Luisa L ^b,c   Richardson, Harriet ^d   Burchell, Ann N ^a,e   Koushik, Anita ^f,g   Mayrand, Marie Hélène ^f,g   Coutlée, François ^f,g   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^d QUEEN S UNIVERSITY   (Canada)

^e ONTARIO HIV TREATMENT NETWORK   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; ARTIFACT; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 52; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; VIRUS LOAD; VIRUS TYPING; ANUS DISEASES; COHORT ANALYSIS; GENETICS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

ANUS DISEASES; COHORT STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84921047448     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0566     Document Type: Article

References (21)

1. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30 Suppl 5:F123-38.
2. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, -2010. J Infect Dis 2013;208: 385-93.
3. Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPVbivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014;110:2804-11.
4. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2010;19:503-10.
5. Vaccarella S, Plummer M, Franceschi S, Gravitt P, Papenfuss M, Smith D, et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis 2011;204:1500-4.
6. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10.
7. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
8. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, et al. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 2006;118:243-5.
9. Mori S, Nakao S, Kukimoto I, Kusumoto-Matsuo R, Kondo K, Kanda T. Biased amplification of human papillomavirusDNAin specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci 2011;102:1223-7.
10. Eklund C, Forslund O, Wallin KL, Zhou T, Dillner J. The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012;50:2289-98.
11. Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 2013;178: 625-34.
12. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Ludwig-McGill Study Group. Rev Panam Salud Publica 1999; 6:223-33.
13. Burchell AN, Tellier PP, Hanley J, Coutlee F, Franco EL. Human papillomavirus infections among couples in new sexual relationships. Epidemiology 2010;21:31-7.
14. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12: 485-90.
15. Koushik A, Ghosh A, Duarte-Franco E, Forest P, Voyer H, Matlashewski G, et al. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detect Prev 2005;29:307-16.
16. Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006; 119:615-23.
17. de Pokomandy A, Rouleau D, Ghattas G, Vezina S, Cote P, Macleod J, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis 2009;199:965-73.
18. Coutlee F, Rouleau D, Ghattas G, Hankins C, Vezina S, Cote P, et al. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J Clin Microbiol 2007;45:3821-3.
19. Gravitt PE, Peyton C, Wheeler C, Apple R, Higuchi R, Shah KV. Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan realtime PCR assays. J Virol Methods 2003;112:23-33.
20. Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006;66:10112-9.
21. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008;46:109-17.